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Abstract
Objectives: Dyspnoea is a common complaint among patients with thyrotoxicosis. However, its
causative mechanisms have not been identified. We assessed the role of thoracic diaphragmatic
muscle weakness in dyspnoea among patients with active Graves’ disease.
Methods: Twenty-seven patients (19 female, 8 male) with active Graves’ disease were assessed for the
clinical severity of dyspnoea, functional (pressure generating capacity) and anatomical aspects
(thickness and excursion) of the diaphragm at presentation. The severity of dyspnoea was assessed
using a visual analogue scale (VAS) and the 6 min walk test. Lung function tests, diaphragmatic
strength (sniff oesophageal pressure, SniffPoeso), maximum inspiratory and expiratory pressures,
diaphragmatic thickness and movements on real time ultrasonography were evaluated during
normal and deep respiration. Twenty of the 27 patients were reassessed after achieving euthyroidism
with carbimazole therapy at a mean interval of 5^2 months.
Results: Reevaluation after carbimazole therapy revealed a significant reduction in dyspnoea on the
VAS 59^26 to 23^13%: Patients covered a similar distance during the 6 min walk before and
after euthyroidism. Significant improvement was observed in the vital capacity 2:57^0:62 to
2:94^0:60 l; forced expiratory volume in the first second 2:21^0:49 to 2:45^0:47 l; total
lung capacity 3:57^1:19 to 4:1^1:12 l; diaphragmatic movement during deep respiration
5:5^1:0 to 6:6^1:1 cm and SniffPoeso 68:7^23 to 93:1^25:2 cmH2O: There was no signifi-
cant change in the distance walked in 6 min, tidal volume, lung diffusion capacity and diaphrag-
matic thickness. There was no significant correlation between the net change in dyspnoea score
and net change in lung function tests, diaphragmatic movement and SniffPoeso.
Conclusions: Significant functional weakness of diaphragm muscle is present in patients with active
Graves’ disease. This weakness is more marked during a maximal respiratory manoeuvre, indicating
a diminished diaphragmatic reserve which could be the cause of dyspnoea observed on exertion
among patients with thyrotoxicosis.
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Introduction
Dyspnoea is a common complaint (82%) among
patients with hyperthyroidism (1). The underlying
patho-physiological mechanism remains unexplained,
except when the patient has coexisting tracheal com-
pression due to goiter or has cardiac failure. Studies
assessing maximum inspiratory pressure (MIP) and
expiratory pressure (MEP) at the mouth to evaluate
respiratory muscle weakness in patients with thyro-
toxicosis have given variable results possibly due to
the wide variability in data obtained (2, 3). Currently,
the most accurate and reproducible clinical assessment
of diaphragm muscle strength and its movement is
obtained by oesophageal pressure measurement
during the sniff manoeuvre (SniffPoeso) and real time
ultrasonography respectively (4–7). The diaphragm is
the main muscle for inspiration and accounts for two-
thirds of tidal volume. To our knowledge, there is no
study where diaphragmatic muscle strength, move-
ment and thickness have been assessed before and
after treatment in patients with Graves’ disease. We
report results of our study in a cohort of patients
with active Graves’ disease demonstrating reduced
diaphragm muscle strength at presentation and its
normalisation following treatment.
Materials and methods
The subjects for the study included 27 consecutive
patients with active Graves’ disease (female 19, male
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8, mean body mass index (BMI) 18:5^2:6 kg=m2; age
30:1^10:9 years) attending the Endocrine Clinic of
All India Institute of Medical Sciences, New Delhi.
Patients with thyroid crisis and those with febrile illness
or cardiac problems were excluded. The distribution of
age, sex and BMI corresponded to the usual pattern in
such patients in our population (8–10). Thyrotoxicosis
was diagnosed based on the criteria suggested by Volpe
(11), i.e. Wayne’s clinical score (12) for thyrotoxicosis
.19, serum total tri-iodothyronine (T3), thyroxine
(T4) and thyrotrophin (TSH) in the hyperthyroid
range, a high 2 h and 24 h radioactive iodine uptake
(normal range 2 h  5 – 15%; 24 h  15 – 35%) and
diffuse thyromegaly. The mean duration of symptoms
was 11:2^12:3 months. Wayne’s clinical score for
thyrotoxicosis, severity of dyspnoea, diaphragm
muscle strength, its movement and thickness, lung
function tests, serum T3, T4 and TSH levels were
assessed in all patients after obtaining informed con-
sent. The patients were treated with carbimazole
(10 mg t.i.d. doses). The average time taken to achieve
euthyroidism was 7^2:2 weeks. After achieving
euthyroidism, carbimazole was continued at main-
tenance doses of 10–20 mg/day. None of the
patients received b-blockers. Patients were followed
up at 1-monthly intervals and they continued to
be euthyroid as indicated by a normal Wayne’s
clinical score for thyrotoxicosis (,19) and normal
circulating T3 and T4 levels. Of the 27 patients
included in the study, 20 were reassessed after a
mean follow-up interval of 5^2 months for the
severity of dyspnoea, diaphragmatic muscle strength
and lung function tests.
SniffPoeso was used to assess diaphragmatic strength.
A 10 cm long balloon catheter (PK Morgan Ltd.,
Rainham, Kent, UK) connected by a 100 cm long fine
bore tubing to a Validyne differential pressure trans-
ducer (^150 cmH2O) was used to record intra-
oesophageal pressure on a Grass polygraph (6). Oeso-
phageal pressure at resting end expiration was used
as the zero reference point. Patients were asked to per-
form ten sharp sniffs with a suitable rest period between
the efforts to obtain reproducible readings. Visual feed-
back and encouragement was provided to the subjects
to get the best response. The highest of the recorded
pressures was used for analysis. The mean SniffPoeso
values determined in our laboratory for 23 healthy
controls (14 males and 9 females, mean age 37:3^
10:4; range 20–52 years) was 144^21:4 cmH2O:
SniffPoeso value ,101.8 cm (mean 2 2 S.D.) was con-
sidered as the subnormal (6). The MIP and MEP at
the mouth (recorded from total lung capacity and
residual volume respectively) were measured using a
mercury manometer and converted into cmH2O. The
technique for recording the respiratory muscle pressure
with this simple manometer has been validated in our
laboratory and predication equations for normal
subjects have been derived (13, 14).
Diaphragmatic excursions were measured in a
supine position during tidal breathing and during
vital capacity manoeuvres on the right and left sides
by ultrasonography using a 3.5 MHz sector transducer
(Model ATL, HDI 3000, Philips Bothel, Washington,
USA) (5, 7). A fixed skin position between the mid-cla-
vicular and mid-axillary line was selected symmetri-
cally to obtain a longitudinal plane of the
hemidiaphragm (including the maximum renal bipolar
length). A craniocaudal displacement line was placed
at the depth of the midpoint of the kidney on expiration
and the excursion on inspiration was measured along
this line. The craniocaudal displacement of the dia-
phragm between the end-expiratory position and at
the end-inspiratory position was measured to evaluate
the movement of the diaphragm during tidal breathing.
The same procedure was repeated to obtain a cranio-
caudal displacement of the diaphragm during the
vital capacity manoeuvre. For each manoeuvre, at
least three satisfactory readings were taken and the
highest of the three readings was used for analysis.
The thickness of the diaphragm was measured on
ultrasound at functional residual capacity.
Spirometry (rolling seal electronic spirometer S232;
P K Morgan) measurements included the respiratory
rate, tidal volume, slow vital capacity, forced vital
capacity, forced expiratory volume in the first second
(FEV1), maximum mid-expiratory flow rate (PEF25 – 75)
and peak expiratory flow rate (PEFR). Absolute lung
volumes were measured using a constant volume
whole body plethysmograph (P K Morgan). The pro-
cedure and the explanations given to the subjects
were standardised as per the recommendations of the
American Thoracic Society (15). The diffusion capacity
was measured using the steady state technique. Breath-
lessness was assessed using the 6 min walk test followed
by the oxygen cost diagram test (OCD) (16). Before
carrying out the test, details of the procedure and the
use of the OCD scale were carefully explained to the
patients. In the 6 min walk test, the patient was asked
to cover the maximum distance possible within a
period of 6 min along a flat and straight corridor. The
distance covered was recorded in metres. The patients
were then asked to grade the severity of dyspnoea on
an OCD scale. This is a visual analogue scale consisting
of a line 100 mm in length with descriptive phrases at
various points along the line indicating the oxygen
requirements for different activities. The upper end of
the line indicates ‘no breathlessness’ while the lower
end corresponds to ‘maximum breathlessness’. The
patients were asked to mark the point on this scale
where they became breathless. The distance from the
top of the scale to the mark put by the patient was
measured in millimetres and this was used as an
index of the severity of dyspnoea.
Estimation of circulating total T3 and T4 levels was
done by an in-house RIA using 125I-labelled T3 and
T4 prepared and purified in our laboratory adopting
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the modified chloramine-T technique (17, 18). The
inter- and intra-assay variations ranged from 6 to
8% respectively. Serum TSH was estimated by an
IRMA assay using a commercial kit (Medicorp Inc.,
5800 Royalmount, Montreal, Quebec, Canada). The
normal range for T4, T3 and TSH were 51–154 nmol/l,
1.1 –2.9 nmol/l and 0.3 –4 mU/l respectively.
Analysis
Data are presented as means^S.D. The paired t-test was
used to assess the significance of the difference in the
means of the SniffPoeso, diaphragm excursion and
thickness, lung function tests, dyspnoea index on the
OCD test and 6 min walk test before and after carbima-
zole therapy. Variables not normally distributed (serum
T4, TSH, dyspnoea index, MEP and MIP) were log trans-
formed and then subjected to a paired t-test. However,
data shown in Table 1 are in the non-transformed
form. Pearson’s correlation coefficient was used to
assess correlation among the above parameters in the
hyperthyroid state in the 27 patients recruited for the
study.
Results
Twenty-four of the 27 patients with Graves’ disease had
dyspnoea (88.8%). Table 1 gives the clinical character-
istics of the patients, severity of dyspnoea, diaphragm
function indices and lung function tests at the time of
presentation for all the 27 patients with Graves’ disease
and the data obtained on follow-up with carbimazole
therapy in 20 of them. The mean BMI and serum
total T3 and T4 improved significantly after treatment
and on follow-up all the patients had become clinically
and biochemically euthyroid. There was a significant
improvement in the subjective assessment of breathless-
ness on the OCD scale after treatment. However, this
was not accompanied by significant improvement in
the distance covered during the 6 min walk test.
The strength of the diaphragmatic muscle contrac-
tion, as measured by SniffPoeso was below normal
in 26 of 27 patients (96.2%) at presentation. It
improved with carbimazole therapy in all the 20
patients at 5^2 months of follow-up (Fig. 1). Only
nine (45%) of them had subnormal values post-
treatment (pre- vs post-treatment, P , 0:01). There
was a significant improvement in the mean SniffPoeso
value P , 0:0001: On ultrasonography, a significant
increase in the excursion of the diaphragm on deep
respiration (vital capacity manoeuvre) was observed
after treatment. However, the mean diaphragmatic
excursion during the normal respiration (tidal volume
manoeuvre) and diaphragm muscle thickness did not
differ significantly before and after carbimazole therapy
(Table 1).
Lung function tests in the untreated thyrotoxic state
showed a diminished mean absolute vital capacity,
which was 75.9% of the predicted value using the
equation-prediction norms in our laboratory. Following
treatment it increased significantly and reached up to
Table 1 Basal data (means ^ S.D.) of 27 patients with thyrotoxicosis and comparison of pre- and post-treatment values (n = 20).
Pre- and post-treatment data in
patients who came for follow-up
(n = 20)
Parameters All patients (n = 27) Pre-treatment Post-treatment P
Age (years) 30.1^10.9 26.6^9.1 — —
Female:male 19:8 15:5 — —
BMI (kg/m2) 18.5^2.6 19.2^2.6 21.8^2.6 ,0.0001
Pulse rate (per min) 106^8 104^8 85^6 ,0.001
Serum total T3 (nmol/l) 8.6^3.1 9.1^3.1 2.6^1.2 ,0.0001
Serum total T4 (nmol/l) 277.9^87.5 287.0^93.9 84.4^38.6 ,0.001
Serum TSH (mU/l) 0.05^0.05 0.05^0.06 0.99^1.9 0.13
Dyspnoea index (%) 56.6^27.9 59.0^26.0 23.0^13.0 ,0.0001
Distance covered in 6 min OCD test (m) 551.3^63.5 549.2^62.1 552.7^62.1 0.83
Diaphragm movement in normal respiration (cm) 2.0^0.4 2.0^0.4 1.8^0.2 0.14
Diaphragm movement in deep respiration (cm) 5.4^0.2 5.5^1.1 6.6^1.1 ,0.01
Diaphragm thickness (mm) 2.0^0.4 2.0^0.5 2.0^0.3 0.42
Vital capacity (l) 2.6^0.7 2.6^0.6 2.9^0.6 ,0.0001
FEV1 (l) 2.2^0.6 2.2^0.5 2.4^0.5 ,0.01
FEF25–75 (l/s) 2.7^1.0 2.6^0.9 2.7^0.8 0.75
Residual volume (l) 1.1^0.6 1.1^0.7 1.1^0.5 0.92
Total lung capacity (l) 3.6^0.2 3.6^1.2 4.1^1.1 0.01
Respiratory rate (per min) 27^5 27^5 23^4 0.02
MEP (cmH2O) 69.0^25.1 72.6^18.4 92.4^35.6 0.11
MIP (cmH2O) 70.3^19.8 68.6^17.1 80.6^30.3 0.16
SniffPoeso (cmH2O) 66.0^22.7 68.7^23.1 93.1^25.2 ,0.0001
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89.9% of the predicted norms P , 0:0001: The
absolute and predicted mean values for the total lung
capacity, FEV1 and PEFR also improved significantly
after the patients became euthyroid (Table 1) and
the respiratory rate showed a significant decline
P , 0:05:
The MIP and MEP measured at the mouth before
treatment were lower than the values predicted for
our laboratory. Although these pressures increased
after treatment, the difference did not attain statistical
significance. The tidal and residual volumes as well as
the diffusion capacity were within the normal limits
before treatment and showed no significant change
after carbimazole therapy (Table 1).
When all the 27 patients were analysed as a group,
there was a significant correlation between the dys-
pnoea index and diaphragm excursion during normal
respiration P , 0:001: However, no significant corre-
lation was observed between the dyspnoea index (6 min
walk and OCD tests) and the severity of thyrotoxicosis
(as evaluated by Wayne’s score and circulating total
T3 and T4 levels), the SniffPoeso, diaphragmatic thick-
ness and its excursions, and the lung function tests.
Discussion
In the present study 88.8% of patients with active
Graves’ disease had dyspnoea. The various factors
which could lead to the high prevalence of dyspnoea
in patients with thyrotoxicosis include an increased
ventilatory drive, airway resistance, diminished lung
compliance and respiratory muscle weakness (1). In
an earlier study, we had observed a significant improve-
ment in dyspnoea, vital capacity and MIP and MEP
measured at the mouth following carbimazole therapy
in patients with active Graves’ disease (19). Similar
observation has been made by other investigators
when MIP and MEP at the mouth were used to
assess respiratory muscle strength in patients with
thyrotoxicosis (2, 3, 20).
In the present study, subnormal pressures were
observed in the thyrotoxic state when SniffPoeso was
used as an index of global inspiratory muscle and
thoracic diaphragm strength (Fig. 1). This observation
together with the significant improvement and even
reversion of SniffPoeso to normal following treatment
indicated the presence of respiratory muscle weakness
in patients with thyrotoxicosis. A significant improve-
ment in vital capacity and an increase in the maximum
inspiratory and expiratory muscle pressures also indi-
cated respiratory muscle weakness in them. The
above changes were not associated with significant
change in the tidal volume. These observations
collectively indicated that respiratory muscle weakness
may manifest in patients with thyrotoxicosis during
excessive physical effort and increased oxygen
demand. A significant increase in diaphragmatic
muscle excursion on deep respiration after carbimazole
therapy, but absence of similar change on normal
respiratory effort, also supports the above observation.
Meir et al. (20) measured SniffPoeso in four patients
with thyrotoxicosis and found it to be on the lower
limit of the normal range in three of them and below
normal in one patient. SniffPoeso improved in all of
them after they became euthyroid. However, since
only four patients were included in this study, it was
not possible to draw any conclusion about the
diaphragmatic weakness (20). McElvaney et al. (3)
reported reduced MIP and MEP and the presence of
respiratory muscle weakness in patients with thyro-
toxicosis, but could not correlate it with their dyspnoea
intensity score. In the present study we could not
demonstrate any correlation among the physiological
parameters measured by the lung function tests,
excursion of the diaphragm on deep respiration and
SniffPoeso pressures. This lack of correlation could be
because the onset of the disease is insidious and the
patients may slowly adapt to the symptom of dyspnoea.
Alternatively, such a lack of correlation could be due to
the fact that the perception of dyspnoea involves a
combination of physiological and psychological factors.
In the present study we did not assess the role of
Figure 1 SniffPoeso tracing in a patient with Graves’ disease
(a) before (71 cmH2O) and (b) after carbimazole therapy
(115 cmH2O).
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psychological factors which could be contributing to
the dyspnoea in patients with thyrotoxicosis.
The mechanism by which the respiratory muscle
strength is improved once patients become euthyroid
is not known. Significant improvement in the vital
capacity following attainment of euthyroidism may
apparently seem to contribute to the improvement in
MEP due to the length tension properties of the respir-
atory muscles. However, there was no change in the
residual volume and therefore it is likely that a true
increase in the strength of the inspiratory muscle has
occurred. Recently, Norrelund et al. (21) assessed
muscle mass of the thigh by computerised tomography
and body composition in patients with thyrotoxicosis. A
decrease in BMI and 20% reduction in skeletal muscle
mass were observed during thyrotoxicosis, which
reversed after 9 months of carbimazole therapy (21).
In the present study, although there was a significant
increase in BMI following a mean interval of 5
months of carbimazole therapy, this was not
accompanied by an increase in the diaphragm muscle
thickness. A shorter duration of follow-up, i.e. 5
months instead of 9 months, and limited sensitivity of
the ultrasonography with a 3.5 MHz transducer may
be the reasons for the non-documentation of an
increase in the thoracic diaphragm muscle thickness
in our study.
In an earlier study, we have described dyssynergia of
the detrusor muscle as the cause of urinary bladder
dysfunction in patients with thyrotoxicosis, which
reversed on treatment (8). It is possible that dys-
synergia of the thoracic diaphragm muscle might
have contributed to poor diaphragmatic muscle
pressure and its movement during deep respiration.
Electromyography studies of the thoracic muscle
diaphragm in patients with thyrotoxicosis may reveal
such changes.
Thus, the present study reveals that patients with
active Graves’ disease have significant functional
weakness of diaphragm muscle. This weakness is
more marked during maximal respiratory manoeuvre,
indicating a diminished diaphragmatic reserve which
could cause the dyspnoea on exertion among patients
with thyrotoxicosis.
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